Homozygosity for UGT1A1*28 influences adverse effects and dose reduction in metastatic pancreatic ductal adenocarcinoma patients treated with NALIRIFOX, suggesting genetic considerations.
AIMS: homozygosity on the safety profile of NALIRIFOX (liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in NAPOLI 3 (NCT04083235). METHODS: status in patients with mPDAC receiving NALIRIFOX or gemcitabine plus nab-paclitaxel in NAPOLI 3. All patients receiving NALIRIFOX initiated liposomal irinotecan at the full starting dose. The most common any-grade TEAEs for NALIRIFOX were diarrhea (59.0%), nausea (56.4%), vomiting (46.2%), and anemia (41.0%) in the homozygous group and diarrhea (71.6%), nausea (59.8%), vomiting (38.4%), and decreased appetite (38.1%) in the other genotypes group. Rates of TEAE-related treatment discontinuation and dose reduction/interruption in the NALIRIFOX arm were similar across genotypes. CONCLUSIONS: status. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT04083235; EudraCT 2018-003585-14.
No takes yet. Share an insight, caveat, or question.
Abdelrahim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: